142 related articles for article (PubMed ID: 19304323)
21. A close link between Fas, p53 and Apaf-1 in chronic myeloid leukemia.
Alenzi FQ; Wyse RK; Tamimi WG; Bamaga MS; Lotfy M
Saudi Med J; 2007 Jul; 28(7):1119-21. PubMed ID: 17603723
[TBL] [Abstract][Full Text] [Related]
22. Malondialdehyde and protein carbonyl as biomarkers for oxidative stress and disease progression in patients with chronic myeloid leukemia.
Ahmad R; Tripathi AK; Tripathi P; Singh S; Singh R; Singh RK
In Vivo; 2008; 22(4):525-8. PubMed ID: 18712183
[TBL] [Abstract][Full Text] [Related]
23. Genomic profile of chronic myelogenous leukemia: Imbalances associated with disease progression.
Brazma D; Grace C; Howard J; Melo JV; Holyoke T; Apperley JF; Nacheva EP
Genes Chromosomes Cancer; 2007 Nov; 46(11):1039-50. PubMed ID: 17696194
[TBL] [Abstract][Full Text] [Related]
24. Aberrant methylation of the death-associated protein kinase 1 (DAPK1) CpG island in chronic myeloid leukemia.
Qian J; Wang YL; Lin J; Yao DM; Xu WR; Wu CY
Eur J Haematol; 2009 Feb; 82(2):119-23. PubMed ID: 19018866
[TBL] [Abstract][Full Text] [Related]
25. The role of aberrant transcription factor in the progression of chronic myeloid leukemia.
Zhang S
Leuk Lymphoma; 2008 Aug; 49(8):1463-9. PubMed ID: 18766960
[TBL] [Abstract][Full Text] [Related]
26. Mutation analysis of the FAS and TNFR apoptotic cascade genes in hematological malignancies.
Rozenfeld-Granot G; Toren A; Amariglio N; Brok-Simoni F; Rechavi G
Exp Hematol; 2001 Feb; 29(2):228-33. PubMed ID: 11166462
[TBL] [Abstract][Full Text] [Related]
27. The negative prognostic impact of derivative 9 deletions in patients who received hydroxyurea treatment for chronic myelogenous leukemia in the chronic phase.
Li JY; Xu W; Wu W; Zhu Y; Qiu HR; Zhang R; Zhang SJ; Qian SX
Onkologie; 2008 Nov; 31(11):585-9. PubMed ID: 19145090
[TBL] [Abstract][Full Text] [Related]
28. The impact of gene profiling in chronic myeloid leukaemia.
Yong AS; Melo JV
Best Pract Res Clin Haematol; 2009 Jun; 22(2):181-90. PubMed ID: 19698927
[TBL] [Abstract][Full Text] [Related]
29. Telomeres and telomerase in chronic myeloid leukaemia: impact for pathogenesis, disease progression and targeted therapy.
Keller G; Brassat U; Braig M; Heim D; Wege H; Brümmendorf TH
Hematol Oncol; 2009 Sep; 27(3):123-9. PubMed ID: 19569255
[TBL] [Abstract][Full Text] [Related]
30. Chronic myelogenous leukemia showing biphenotypic blast crisis followed by lineage switch to B lymphoblastic leukemia.
Oh SH; Park TS; Kim HR; Lee JY; Kim JH; Shin JH; Lee JN
Leuk Res; 2009 Nov; 33(11):e195-8. PubMed ID: 19446879
[TBL] [Abstract][Full Text] [Related]
31. Chronic myelogenous leukemia, BCR-ABL1+.
Vardiman JW
Am J Clin Pathol; 2009 Aug; 132(2):250-60. PubMed ID: 19605820
[TBL] [Abstract][Full Text] [Related]
32. Analysis of copy number variations of BS69 in multiple types of hematological malignancies.
Yang H; Zhang C; Zhao X; Wu Q; Fu X; Yu B; Shao Y; Guan M; Zhang W; Wan J; Huang X
Ann Hematol; 2010 Oct; 89(10):959-64. PubMed ID: 20425112
[TBL] [Abstract][Full Text] [Related]
33. Chronic myeloid leukemia in blast phase associated with t(3;8)(q26;q24).
Lin P; Lennon PA; Yin CC; Abruzzo LV
Cancer Genet Cytogenet; 2009 Sep; 193(2):119-22. PubMed ID: 19665075
[TBL] [Abstract][Full Text] [Related]
34. GATA2 gene analysis in several forms of hematological malignancies including familial aggregations.
Hamadou WS; Mani R; Besbes S; Bourdon V; Youssef YB; Eisinger F; Mari V; Gesta P; Dreyfus H; Bonadona V; Dugast C; Zattara H; Faivre L; Noguchi T; Khélif A; Sobol H; Soua Z
Ann Hematol; 2017 Oct; 96(10):1635-1639. PubMed ID: 28752392
[TBL] [Abstract][Full Text] [Related]
35. sFRP1 promoter methylation is associated with persistent Philadelphia chromosome in chronic myeloid leukemia.
Pehlivan M; Sercan Z; Sercan HO
Leuk Res; 2009 Aug; 33(8):1062-7. PubMed ID: 19118898
[TBL] [Abstract][Full Text] [Related]
36. p210(Bcr-Abl) desensitizes Cdc42 GTPase signaling for SDF-1alpha-directed migration in chronic myeloid leukemia cells.
Chang YC; Tien SC; Tien HF; Zhang H; Bokoch GM; Chang ZF
Oncogene; 2009 Nov; 28(46):4105-15. PubMed ID: 19718053
[TBL] [Abstract][Full Text] [Related]
37. Technical aspects and clinical applications of measuring BCR-ABL1 transcripts number in chronic myeloid leukemia.
Foroni L; Gerrard G; Nna E; Khorashad JS; Stevens D; Swale B; Milojkovic D; Reid A; Goldman J; Marin D
Am J Hematol; 2009 Aug; 84(8):517-22. PubMed ID: 19544476
[TBL] [Abstract][Full Text] [Related]
38. Jumping translocations in hematological malignancies: a cytogenetic study of five cases.
Manola KN; Georgakakos VN; Stavropoulou C; Spyridonidis A; Angelopoulou MK; Vlachadami I; Katsigiannis A; Roussou P; Pantelias GE; Sambani C
Cancer Genet Cytogenet; 2008 Dec; 187(2):85-94. PubMed ID: 19027489
[TBL] [Abstract][Full Text] [Related]
39. [Review of relationship between tumor necrosis factor genetic polymorphism and hematological malignancies].
Zhao HY; Chen YX
Ai Zheng; 2003 Feb; 22(2):216-20. PubMed ID: 12600304
[TBL] [Abstract][Full Text] [Related]
40. Small MAF genes variants and chronic myeloid leukemia.
Martínez-Hernández A; Gutierrez-Malacatt H; Carrillo-Sánchez K; Saldaña-Alvarez Y; Rojas-Ochoa A; Crespo-Solis E; Aguayo-González A; Rosas-López A; Ayala-Sanchez JM; Aquino-Ortega X; Orozco L; Cordova EJ
Eur J Haematol; 2014 Jan; 92(1):35-41. PubMed ID: 24118457
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
